Not all antibodies are equal

Por Booth, Laurence
Publicado em 2013

Repurposing Tecfidera for cancer

Por Booth, Laurence, Malkin, Mark, Dent, Paul
Publicado no Aging (Albany NY) (2016)

Not the comfy chair! Cancer drugs that act against multiple active sites

Por Booth, Laurence, Poklepovic, Andrew, Dent, Paul
Publicado no Expert Opin Ther Targets (2019)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies

Por Dent, Paul, Booth, Laurence, Poklepovic, Andrew
Publicado no Immunometabolism (2019)

HSPA5/Dna K May Be a Useful Target for Human Disease Therapies

Por Booth, Laurence, Roberts, Jane L., Dent, Paul
Publicado no DNA Cell Biol (2015)

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species

Por Roberts, Jane L., Poklepovic, Andrew, Booth, Laurence
Publicado no Oncotarget (2017)

The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells

Por Booth, Laurence, Roberts, Jane, Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2018)

The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib

Por Booth, Laurence A., Roberts, Jane L., Dent, Paul
Publicado no Semin Cancer Biol (2019)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]

Por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Publicado no Oncotarget (2017)

[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells

Por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2017)

Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody

Por Booth, Laurence, Roberts, Jane Lisa, Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2018)

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells

Por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Publicado no Oncol Signal (2017)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib

Por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Publicado no Front Oncol (2019)

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

Por Booth, Laurence, West, Cameron, Hoff, Daniel Von, Dent, Paul
Publicado no Front Oncol (2020)

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic

Por Tavallai, Mehrad, Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Publicado no Front Oncol (2016)

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide

Por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Gordon, Sarah, Dent, Paul
Publicado no Oncotarget (2016)

HDAC inhibitors enhance the immunotherapy response of melanoma cells

Por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Kirkwood, John, Dent, Paul
Publicado no Oncotarget (2017)

Valproate augments Niraparib killing of tumor cells

Por Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2018)

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells

Por Booth, Laurence, Roberts, Jane L., Kirkwood, John, Poklepovic, Andrew, Dent, Paul
Publicado no Adv Cancer Res (2018)

Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition

Por Booth, Laurence, Roberts, Jane L., Spiegel, Sarah, Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2018)